advanced non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
National Hospital Organization Shikoku Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Histologically or cytologically (excluding sputum cytology) confirmed to be NSCLC. (Mixed types are excluded if they contain small cell carcinoma.) (ii) Patients have clinical stage III or IV (according to UICC-TNM 8th edition) or postoperative recurrent NSCLC for which radical resection or radical radiotherapy is not possible without systemic chemotherapy. (iii) ICI with or without chemo as indicated below is initiated as initial systemic chemotherapy from January 2019 to October 2021. However, if systemic chemotherapy (excluding cases treated with ICI) is given as postoperative chemotherapy, the patient is eligible if more than 6 months have elapsed since the last administration of that chemotherapy. (iv) The patient has been confirmed to be non-PD for at least 3 months after the start of ICI+chemo treatment.
Exclusion criteria
Exclusion criteria: (1) Patients have multiple cancers with a disease-free interval of less than 1 year at the time of ICI with or without chemo treatment. (Disease-free intervals are acceptable if the epithelial and intramucosal cancer lesions are judged to be curable by local treatment. (2) History of ICI treatment prior to initiation of ICI with or without chemo treatment. (iii) Recurrence after radical thoracic radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy and safety of initial immune checkpoint inhibitor with or without cytotoxic chemotherapy | — |
Countries
Japan
Contacts
Public ContactTakashi Ninomiya
National Hospital Organization Shikoku Cancer Center Department of Thoracic Oncology and Medicine
Outcome results
None listed